Abstract
There is a growing interest in sleep disorders in multiple sclerosis (MS) due to their high frequency and possible relationship to fatigue, a hallmark symptom in MS. Among them, insomnia and restless legs syndrome (RLS) are the most common ones. RLS is a sleep-related motor disorder characterized by a strong urge to move associated with uncomfortable sensations in the limbs. It is frequently under diagnosed in patients with MS although its course is often particularly severe. Several arguments support a symptomatic origin of RLS in MS patients. Independently of any causal relationship, the high prevalence of RLS in MS patients has clinical implications.
The purpose of the present review is (i) to summarize the epidemiological data and clinical characteristics of RLS in MS patients in order to increase sensitivity to this disorder; (ii) to document the substantial body of evidence in support of a symptomatic origin of RLS in MS and from this (iii) to delineate the proposition that MS may represent a clinical model to study RLS-associated pathological changes.Keywords: MS, restless legs syndrome, sleep disorders, insomnia, epidemiological, secondary progressive form, pathological brain, autoimmune, hypersomnia, parasomnias.
CNS & Neurological Disorders - Drug Targets
Title:Restless Legs Syndrome in Multiple Sclerosis
Volume: 11 Issue: 8
Author(s): Chiara Zecca, Mauro Manconi, Stephany Fulda and Claudio Gobbi
Affiliation:
Keywords: MS, restless legs syndrome, sleep disorders, insomnia, epidemiological, secondary progressive form, pathological brain, autoimmune, hypersomnia, parasomnias.
Abstract: There is a growing interest in sleep disorders in multiple sclerosis (MS) due to their high frequency and possible relationship to fatigue, a hallmark symptom in MS. Among them, insomnia and restless legs syndrome (RLS) are the most common ones. RLS is a sleep-related motor disorder characterized by a strong urge to move associated with uncomfortable sensations in the limbs. It is frequently under diagnosed in patients with MS although its course is often particularly severe. Several arguments support a symptomatic origin of RLS in MS patients. Independently of any causal relationship, the high prevalence of RLS in MS patients has clinical implications.
The purpose of the present review is (i) to summarize the epidemiological data and clinical characteristics of RLS in MS patients in order to increase sensitivity to this disorder; (ii) to document the substantial body of evidence in support of a symptomatic origin of RLS in MS and from this (iii) to delineate the proposition that MS may represent a clinical model to study RLS-associated pathological changes.Export Options
About this article
Cite this article as:
Zecca Chiara, Manconi Mauro, Fulda Stephany and Gobbi Claudio, Restless Legs Syndrome in Multiple Sclerosis, CNS & Neurological Disorders - Drug Targets 2012; 11 (8) . https://dx.doi.org/10.2174/1871527311211080017
DOI https://dx.doi.org/10.2174/1871527311211080017 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Neuropeptides and Neurohormones in Neurogenic Cardiac Arrhythmias
Current Drug Targets - Cardiovascular & Hematological Disorders Bedtime Hypertension Chronotherapy: Concepts and Patient Outcomes
Current Pharmaceutical Design Biologic Therapy and Treatment Options in Diabetic Retinopathy with Diabetic Macular Edema
Current Drug Safety Stroke and Neuroinflamation: Role of Sexual Hormones
Current Pharmaceutical Design Possible Direct Influence of Complement 3 in Decreasing Insulin Sensitvity in a Cohort of Overweight and Obese Subjects
Endocrine, Metabolic & Immune Disorders - Drug Targets Lipases as Modulators of Atherosclerosis in Murine Models
Current Drug Targets Exercise and Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein 1: Recent Developments Concerning Substrates and Inhibitors of a Promising Therapeutic Target
Current Medicinal Chemistry Incidence and Prevalence of Hypothyroidism in Patients Affected by Chronic Heart Failure: Role of Amiodarone
Endocrine, Metabolic & Immune Disorders - Drug Targets Enzymes To Die For: Exploiting Nucleotide Metabolizing Enzymes for Cancer Gene Therapy
Current Gene Therapy Application of Hematopoietic Cells to Therapeutic Angiogenesis
Current Pharmaceutical Design An insight into the Interaction between Clopidogrel and Proton Pump Inhibitors
Current Drug Metabolism An Overview of Nanoformulated Nutraceuticals and their Therapeutic Approaches
Current Nutrition & Food Science The Immunoproteasome as a Therapeutic Target for Hematological Malignancies
Current Cancer Drug Targets Variation of Antioxidant Capacity in Different Layers of Onion (Allium cepa L.) At Two Different Stages of Maturation
Current Nutrition & Food Science Editorial [Hot Topic: Oxidative Stress Induced-Metabolic Imbalance, Mitochondrial Failure, And Cellular Hypoperfusion As Primary Pathogenetic Factors For The Development Of Alzheimer Disease Which Can Be Used As An Alternate And Successful Drug Treatment Strategy: Past, Present And Future (Guest Editor: Gjumrakch Aliev)]
CNS & Neurological Disorders - Drug Targets Low Lymphocyte Count and Cardiovascular Diseases
Current Medicinal Chemistry Aldose Reductase: A Multi-disease Target
Current Enzyme Inhibition Novel Drugs Targeting the c-Ring of the F<sub>1</sub>F<sub>O</sub>-ATP Synthase
Mini-Reviews in Medicinal Chemistry Neuroprotective Properties of Erythropoietin in Cerebral Ischemia
Central Nervous System Agents in Medicinal Chemistry